AI Breakthrough: New Framework Predicts Cancer Treatment Success, Boosts Survival by 15%
AstraZeneca and Tempus AI have unveiled a predictive biomarker modeling framework leveraging contrastive learning, LLMs, and machine learning to forecast treatment responses in immuno-oncology trials. The innovation delivers a 15% survival advantage over traditional methods, paving the way for precision cancer care.